Navigation Links
Proteolix to Present Carfilzomib Clinical Data During the 2009 ASCO Annual Meeting
Date:5/15/2009

Results from Phase 2 Clinical Trials of Carfilzomib in Relapsed/Refractory Multiple Myeloma and Advanced Solid Tumors Featured in Oral Presentations

SOUTH SAN FRANCISCO, May 15 /PRNewswire/ -- Proteolix, Inc. today announced that data from clinical trials of carfilzomib in multiple myeloma and advanced solid tumors will be presented at the 2009 Annual Meeting of the American Society of Clinical Oncology (ASCO) being held May 29 - June 2, 2009 in Orlando, Florida. Carfilzomib is the first in a new class of selective, irreversible proteasome inhibitors and is currently enrolling patients in an accelerated approval study in relapsed/refractory multiple myeloma and Phase 2 clinical studies in relapsed multiple myeloma and other malignancies.

Of note, results from Proteolix's Phase 2 study of carfilzomib for the treatment of patients with relapsed and refractory multiple myeloma will be presented on Monday, June 1 during an oral session by Sundar Jagannath, M.D., Chief of the Multiple Myeloma Program, Bone Marrow and Blood Stem Cell Transplantation at St. Vincent's Comprehensive Cancer Center in New York. The Phase 2 trial is an open-label multi-center study of single-agent carfilzomib in patients who have previously failed at least two prior treatments, containing bortezomib and either lenalidomide or thalidomide, and are refractory to their last treatment. In addition, results from a Phase Ib/II study of carfilzomib in patients with selected advanced metastatic solid tumors will be presented on Saturday, May 30 during an oral session by Peter Rosen, M.D., Medical Director, Tower Cancer Research Foundation and Emeritus Professor, UCLA.

A complete list of the company's oral and poster presentations at ASCO follows:

    Oral Presentations
      Saturday, May 30, 2009 at 5:00 p.m. ET
      Track: Developmental Therapeutics
      Session: Developmental Therapeutics: Molecular
'/>"/>
SOURCE Proteolix, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Proteolix Announces New Appointment in Finance and Expands Clinical and Regulatory Leadership Team
2. Proteolix Announces Positive Data From Two Ongoing Phase 2 Clinical Trials of Carfilzomib in Multiple Myeloma at the 50th Annual Meeting of the American Society of Hematology
3. Proteolix Presents Preclinical Data for Oral Proteasome Inhibitor PR-047 at the 50th Annual Meeting of the American Society of Hematology
4. Proteolix Raises $79 Million in Series C Financing
5. Proteolixs Carfilzomib Receives Orphan Drug Designation for Treatment of Multiple Myeloma
6. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
7. China Biologic Products to Present at CCG IRs China Rising Conference and Oppenheimers China Dragon Call Conference in New York
8. EntreMed ENMD-2076 Phase 1 Data to Be Presented at ASCO Annual Meeting
9. Oncolytics Biotech(R) Inc.s Research Collaborators to Present Data on REOLYSIN(R) Clinical Trials at ASCO Conference
10. Trubion Announces Acceptance of Three Presentations on Its TRU-016 Product Candidate at the 2009 ASCO Annual Meeting
11. Bayer and Onyx Announce Nexavar Data Presentations at 45th American Society of Clinical Oncology Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... 22, 2015 Protocol Networks brings independent ... team of brand-neutral, independent consultants, Protocol Networks has recently ... that over the years, his company has attracted several ... of Plainfield, as well as others. With the success ...
(Date:1/22/2015)... January 22, 2015 Controlled Substance Compliance ... which helps companies check the legal requirements around using ... to China. , As their international operations expand ... adopting software solutions built as a result of the ...
(Date:1/22/2015)...  Varian Medical Systems (NYSE: VAR ), world leader ... commitment to sustainability with inclusion on a prestigious list of ... healthcare equipment company among the Corporate Knights Global 100 Most ... at Davos, Switzerland . ...
(Date:12/24/2014)... and NEW YORK , Dec. 24, 2014 ... advancing patient care in critical areas, announced the closing of ... and warrants to purchase up to an aggregate 3,500,000 shares ... share and $.01 per warrant.  The warrants have a per ...
Breaking Biology Technology:Protocol Networks Brings Independent Technology Consulting to the Constitution State 2Global Compliance Service for Controlled Substances to Expand to China 2Varian Honored Among World's 100 Most Sustainable Corporations 2PlasmaTech Biopharmaceuticals, Inc. Announces Closing of Public Offering 2PlasmaTech Biopharmaceuticals, Inc. Announces Closing of Public Offering 3
... Board: SYMD), a biomaterials company engaged in the development,and ... Robert P. Hickey, President and CEO, will present at,the ... 2007 at,5:05 PM, EDT, at the New York Palace ... company overview. The presentation will be available via ...
... the Delft University of Technologys Kavli Institute of Nanoscience ... have succeeded in controlling the spin of a single ... way for a much simpler realization of the building ... will publish their work in Science Express on Thursday ...
... Anadys Pharmaceuticals,Inc. (Nasdaq: ANDS ), a biopharmaceutical ... medicines in the areas of hepatitis C and,oncology, ... quarter ended,September 30, 2007 and operational highlights. ... transition for Anadys,",said Steve Worland, Ph.D., President and ...
Cached Biology Technology:Delft University of Technology rotates electron spin with electric field 2Anadys Pharmaceuticals Reports Third Quarter 2007 Financial Results and Operational Highlights 2Anadys Pharmaceuticals Reports Third Quarter 2007 Financial Results and Operational Highlights 3Anadys Pharmaceuticals Reports Third Quarter 2007 Financial Results and Operational Highlights 4Anadys Pharmaceuticals Reports Third Quarter 2007 Financial Results and Operational Highlights 5Anadys Pharmaceuticals Reports Third Quarter 2007 Financial Results and Operational Highlights 6Anadys Pharmaceuticals Reports Third Quarter 2007 Financial Results and Operational Highlights 7Anadys Pharmaceuticals Reports Third Quarter 2007 Financial Results and Operational Highlights 8Anadys Pharmaceuticals Reports Third Quarter 2007 Financial Results and Operational Highlights 9
(Date:12/22/2014)... Dec. 22, 2014 Research and Markets ... the "The Global Watermarking and Fingerprinting Markets" ... http://photos.prnewswire.com/prnh/20130307/600769 This insight ... watermarking and fingerprinting markets. Watermarking aims to control ...
(Date:12/19/2014)... VEGAS , Dec. 18, 2014   LaunchKey , ... for the post-password and Internet of Things era, today ... funding. The venture round was led by Metamorphic Ventures ... Rimrock Venture Partners, VegasTechFund, and others.  LaunchKey has raised ...
(Date:12/17/2014)... Research and Markets ( http://www.researchandmarkets.com/research/9zq33j/global_chemical ) has ... Market 2015-2019" report to their offering. ... trend upcoming in this market is the increasing demand ... in recording of patient data for quick and correct ...
Breaking Biology News(10 mins):The Global Watermarking and Fingerprinting Markets 2LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 2LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 3Global Chemical Sensor Market 2015-2019: Key Vendors are Abbott Laboratories, Bayer, Hoffmann La-Roche, Johnson & Johnson, NGK Spark Plugs and Robert Bosch 2
... May 30, 2011 Reportlinker.com announces that ... in its catalogue: Enzymes ... http://www.reportlinker.com/p0535955/Enzymes-in-Drug-Manufacturing.html?utm_source=prnewswire&utm_medium=pr&utm_campaign=Biopharmaceutical Biocatalysis in pharmaceutical ... enzyme and genomics technologies that are increasing ...
... Nature a new molecular pathway used to suppress blood ... potential therapeutic value for fighting diseases of the retina and ... blood cells involved in the immune system, use this molecular ... in the same study researchers were able to reverse this ...
... drugs to combat or cure human disease often involves a ... clearly into a living mouse,s innards has real value. ... interior of laboratory mice, the view becomes so murky several ... divining the future from the rodent,s entrails than they do ...
Cached Biology News:Reportlinker Adds Enzymes in Drug Manufacturing 2Reportlinker Adds Enzymes in Drug Manufacturing 3Reportlinker Adds Enzymes in Drug Manufacturing 4Reportlinker Adds Enzymes in Drug Manufacturing 5Reportlinker Adds Enzymes in Drug Manufacturing 6Novel pathway regulating angiogenesis may fight retinal disease, cancers 2Better viewing through fluorescent nanotubes when peering into innards of a mouse 2Better viewing through fluorescent nanotubes when peering into innards of a mouse 3
Antibody specific for trimethyl-Lys27 of histone H3. Mouse monoclonal. Antigen: Synthetic peptide derived from histone H3, trimethylated at lysine 27...
DL-Dithiothreitol (Clelands Reagent) ,PROTEASE FREE!! ,Molecular Biology Grade ,PRODUCT MUST SHIP NEXT DAY DURING HOT SUMMER MONTHS. ,C 4 H 10 O 2 S 2 ,Molecular Weight: 154.25 ,CAS RN: [27565-...
DTT 50 l...
...
Biology Products: